Newsroom
Sorted by: Latest
-
Venu Holding Corporation to Host Fiscal 2026 Third Quarter Earnings Call
COLORADO SPRINGS, Colo.--(BUSINESS WIRE)--Venu Holding Corporation (“VENU” or the “Company”) (NYSE American: VENU), owner, operator, and developer of premium live entertainment destinations, will host a conference call to discuss financial results and strategic initiatives for its fiscal third quarter ended September 30, 2026, on Monday, November 16 at 11:00 a.m. Eastern Time. The Company anticipates issuing a press release reporting its results prior to market opening. Conference Call Details...
-
Snap-on Raises Dividend 12.7%
KENOSHA, Wis.--(BUSINESS WIRE)--The Snap-on board of directors raised its quarterly dividend to $2.75 per share, from the previous $2.44 per share, an increase of $0.31 or 12.7%....
-
Pulse Biosciences Presents Six-Month Interim Results from the PRECISE-BTN Multicenter Study at the American Thyroid Association Annual Meeting
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), the company leveraging its ever evolving novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced interim six-month results from PRECISE-BTN, a prospective, multicenter U.S. study evaluating the nPulse™ Vybrance™ Percutaneous Electrode System for the treatment of symptomatic and hyperfunctioning benign thyroid nodules (BTNs). The results were presented at the 95th Annual Meet...
-
Algoma Central Corporation Reports Financial Results for the 2026 Third Quarter
ST. CATHARINES, Ontario--(BUSINESS WIRE)--Algoma Central Corporation (TSX: ALC) ("Algoma", the "Company") today reported its results for the three and nine months ended September 30, 2026. Algoma delivered strong third quarter results, with reported revenue of $287,751, an increase of 26% from $228,035 in the third quarter of 2025. Net earnings increased 37% to $54,182, or $1.34 per share, compared with $39,437, or $0.97 per share, in the prior-year period. EBITDA increased to $95,189 from $89,...
-
Sylvamo Releases Third Quarter Earnings
MEMPHIS, Tenn.--(BUSINESS WIRE)--Sylvamo (NYSE: SLVM), the world’s paper company, is releasing third quarter earnings. The company will host an audio webcast at 10 a.m. EST at investors.sylvamo.com. Management Summary from Chief Executive Officer John Sims As we announced earlier this morning, we entered into a put option agreement with Midas Atlantic Partners, in partnership with The Najafi Companies, for a binding offer to acquire our Europe business, including our uncoated freesheet paper mi...
-
Canopy Growth Reports Second Quarter Fiscal Year 2027 Financial Results; Net Revenue Growth of 22% Led by a 141% Increase in International Markets Cannabis
SMITHS FALLS, Ontario--(BUSINESS WIRE)--Canopy Growth Corporation (“Canopy Growth”, “our”, “we” or the “Company”) (TSX: WEED) (Nasdaq: CGC), a leading global company committed to bettering lives through cannabis, today announced its financial results for the three months ended September 30, 2026 ("Q2 FY2027"). All financial information in this press release is reported in Canadian dollars, unless otherwise indicated. “We have made tremendous progress on our international strategy. Our internati...
-
First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)
LONDON--(BUSINESS WIRE)-- Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust US Equity Income UCITS ETF 05.11.2026 UNCU.LN IE00BD6GCF16 1,069,907.00 USD 55,801,828.38 52.156 ...
-
First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)
LONDON--(BUSINESS WIRE)-- Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Global Equity Income UCITS ETF 05.11.2026 GINC LN IE00BD842Y21 913,058.00 USD 61,158,764.84 66.982 ...
-
Lilly and Hims & Hers expand access to FDA-approved Lilly medicines
INDIANAPOLIS--(BUSINESS WIRE)--Eli Lilly and Company (NYSE: LLY) and Hims & Hers Health, Inc. (NYSE: HIMS) today announced an agreement to help expand access to Zepbound (tirzepatide) and Foundayo (orforglipron). Through the agreement, eligible patients who receive a prescription from a licensed provider on the Hims & Hers platform will access the same self-pay prices available to any patient without leaving the Hims & Hers platform. The agreement brings together Lilly’s obesity med...
-
First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)
LONDON--(BUSINESS WIRE)-- Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust US Equity Income UCITS ETF 05.11.2026 UINC IE00BZBW4Z27 10,946,025.00 USD 467,770,990.93 42.734 ...